



The Open Medicinal Chemistry Journal

Content list available at: <https://openmedicinalchemistryjournal.com>



RESEARCH ARTICLE

Novel Benzylamine Derivatives: Synthesis, Anti-*Mycobacterium Tuberculosis* Evaluation and Predicted ADMET Properties

Mmaserole R. Sedibana¹ and Tlabo C. Leboho^{1,*}

¹Department of Chemistry, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, South Africa

Abstract:

Background:

Tuberculosis (TB), a disease caused by the bacillus bacteria *Mycobacterium tuberculosis* is one of the major contributors of ill health in the world. TB is ranked in the top 10 causes of death globally and it is the leading killer associated with a single infectious agent. According to the World Health Organization (WHO), global number of deaths associated with TB have been slowly declining with 1.3 million in reported 2016 and 2017, and 1.2 million reported in 2018 and 2019.

Objective:

The synthesis, characterisation, biological evaluations, and the prediction of ADMET properties of the novel benzylamine derivatives.

Methods:

Commercially available reagents and solvents were purchased from Sigma Aldrich and Merck (South Africa). All chemicals were used as received, unless otherwise stated. The synthesised crude compounds were purified by flash silica gel column chromatography (5 – 30% ethyl acetate in hexane). The successful formation and purity of the synthesised compounds was confirmed by NMR, HRMS and melting point.

Results:

The respective organic compounds were synthesised by treating 3-ethoxysalicylaldehyde, 5-bromo-3-ethoxysalicylaldehyde, 5-chloro-3-ethoxysalicylaldehyde with various aromatic amines and the products were obtained in good to excellent yields. The ¹H and ¹³C NMR spectra of all the products showed the appearance of the methylene signals ranging from 3.88 – 4.68 ppm and 42.25 – 52.57 ppm respectively. Additionally, most compounds showed anti-*Mycobacterium tuberculosis* activity that ranged between 20 and 28 μM.

Conclusion:

A total of 36 compounds were synthesised and successfully biologically evaluated against *Mycobacterium tuberculosis* (Mtb) H37RV strain. All compounds showed activity against Mtb at concentrations of > 20 μM < 28 μM with the exception of compound one that was active against Mtb at higher concentration (MIC₉₀ > 125 μM).

Keywords: Tuberculosis, Mycobacterium, Drugs, Deaths, Disease, WHO.

Article History

Received: September 13, 2022

Revised: December 25, 2022

Accepted: January 19, 2023

1. INTRODUCTION


Tuberculosis (TB), a disease caused by the bacillus bacteria *Mycobacterium tuberculosis* is one of the major contributors to ill health in the world. TB is the top 10 causes of death globally and it is the leading killer associated with a single infectious agent. According to the World Health Organization (WHO), the global number of deaths associated

with TB has been slowly declining with 1.3 million in reported 2016 and 2017, and 1.2 million reported in 2018 and 2019 [1 - 4]. Unfortunately, WHO also reported that the number of people infected with TB has increased from 6.4 million in 2017 to 7.1 million in 2019 [4]. Although significant progress has been achieved towards the development of antitubercular drugs, the emergence of multidrug-resistance tuberculosis (MD-R TB) and extensively drug-resistance tuberculosis (XDR-TB) coupled with the time required to completely cure tuberculosis (3 – 9 months) has compromised the management

* Address correspondence to this author at the Department of Chemistry, Faculty of Science and Agriculture, University of Limpopo, Private Bag X1106, Sovenga 0727, South Africa; Email: Tlabo.leboho@ul.ac.za

of tuberculosis. This compromise has led to the inefficient use of the first-line TB drugs (isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin) mainly due to the development of resistance towards these drugs [5 - 11]. To solve the resistance towards first-line TB drugs, intensive research efforts were directed at finding efficient and better-acting TB drugs. These efforts led to the development of antitubercular drugs such as bedaquiline [12], linezolid [13], delamanid [14] and pretonamid [15] (Fig. 1) as drugs that were aimed at treating MDR-TB and XDR-TB. Despite the successful introduction of these drugs to treat TB, there are still more challenges that still need to be addressed. Some of these challenges include treatment of people with HIV co-infection [16], shortened treatment time and drug costs [17], complicated regimen (number of pills required for the successful treatment) [18], effective and early TB detection [19], suitability of the current drugs for children (pill vs syrup) [20] and the emergence of totally-drug resistance TB (TDR-TB) strain [21]. Therefore, solving some or all these challenges will help WHO in meeting its goals of significantly reducing the burden of TB and subsequently, the reduction of the death toll associated with TB by 90% in 2030 [4]. More intensified research efforts are underway to identify novel methods and drugs for the treatment of TB. For example, studies of high doses of rifapentine as a replacement for rifampin for the shortened treatment time [22] while nanoparticles-based treatment is being explored for directed treatment [23, 24].

Benzylamine-containing compounds have been studied as potential drugs for treating an array of diseases including TB [25]. These investigations include their use as Kallikrein 5 inhibitors [26], Toll-Like Receptor 2 inhibitors [27], antifungal and antibacterial agents [28], possible anticancer agents [29, 30] and antidiabetic agents [31]. In addition to the above-mentioned biological properties, several drugs containing benzylamine have been approved for different ailments. For example, Levocetirizine is used for the treatment of hay fever, Clopidogrel is used as an antiplatelet drug to reduce the risks of heart disease and stroke, Donepezil is used for the treatment of Alzheimer's disease while Mirtazapine is used for the treatment of depression (Fig. 2) [32]. Taking advantage of the remarkable biological properties of benzylamine-containing compounds, here, we report the synthesis of benzylamine derivatives as potential antituberculosis agents. Halogens (iodine and bromine) were introduced on position 5 of the benzylamine to investigate their effect on the properties of the synthesised compounds. The benzylamine derivatives were biologically evaluated (*in vitro*) against *Mtb* H37RV strain while their cytotoxicity was on the Chinese Hamster ovarian (CHO) cell line.



2. EXPERIMENTAL PROCEDURES

2.1. General Information

Commercially available reagents and solvents were purchased from Sigma Aldrich and Merck (South Africa). All chemicals were used as received unless otherwise stated. The structural properties of the compounds were recorded and confirmed by: High-resolution mass spectra were recorded using Sciex X500R QTOF at the University of Limpopo Mass Spectrometry Facility; Melting points were obtained using Lasec/SA-melting point apparatus from Lasec company, SA (Johannesburg, South Africa); IR spectra were recorded using Bruker technologies Alpha Platinum ATR FTIR spectrometer; and Nuclear Magnetic Resonance (NMR) (Bruker Ascend 400 MHz Topspin 3.2); ¹H NMR and ¹³C NMR spectra were referenced internally using solvent signals, ¹H NMR: 7.250 ppm for CDCl₃, 2.500 ppm for DMSO-d₆; ¹³C NMR: 77.00 ppm for CDCl₃, 39.40 ppm for DMSO-d₆, respectively which were used as the solvents at room temperature. Chemical shifts are expressed in δ-values parts per million (ppm) and the coupling constants (*J*) in Hertz (Hz). Multiplicity of the signals is given as follows: brs = broad singlet, s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublet and m = multiplet.

2.1.1. Synthesis of 5-bromo-3-ethoxy-2-hydroxybenzaldehyde 239

Mixture of 2-hydroxy-3ethoxybenzaldehyde (1.500 g, 9.03 mmol) and N-bromo-succinimide (1.606 g, 9.03 mmol, 1 eq.) in acetonitrile (100 mL) for 18 hours. Subsequently, the reaction mixture was quenched with a saturated aqueous solution of ammonium chloride and extracted with ethyl acetate (3 x 30 mL). The combined organic fractions were dried with anhydrous sodium sulphate, solvent was removed on rotary evaporator and the resulting product was purified by flash silica gel column chromatography (5 – 30% ethyl acetate in hexane) to afford 5-bromo-3-ethoxy-2-hydroxybenzaldehyde **2** as a yellowish solid, 2.133 g, 97%. ¹H NMR (400 MHz, CDCl₃) δ 10.96 (s, 1H), 9.84 (s, 1H), 7.29 (d, *J* = 2.2 Hz, 1H), 7.16 (d, *J* = 2.1 Hz, 1H), 4.10 (q, *J* = 7.0 Hz, 2H), 1.49 (t, *J* = 7.0 Hz, 3H).40 HRMS (ESI) [M+H]⁺:m/z 244.1366; Calculated mass for C₉H₉BrO₃ is 243.970.

2.1.2. Synthesis of 3-ethoxy-2-hydroxy-5-iodobenzaldehyde 339

A mixture of 2-hydroxy-3ethoxybenzaldehyde (1.500 g, 9.03 mmol) and N-iodosuccinimide (2.032 g, 9.03 mmol, 1 eq.) was added in acetonitrile (100 mL) for 18 hours. Subsequently, the reaction mixture was quenched with a saturated aqueous solution of ammonium chloride and extracted with ethyl acetate (3 x 30 mL). The combined organic fractions were dried with anhydrous sodium sulphate and solvent was removed on a rotary evaporator and the resulting product was purified by flash silica gel column chromatography (5 – 30% ethyl acetate in hexane) to afford 3-ethoxy-2-hydroxy-5-iodobenzaldehyde **3** as a bright yellow solid, 2.591 g, 98%, mp 94-96 °C. ¹H NMR (400 MHz, CDCl₃) δ 10.98 (s, 1H), 9.83 (s, 1H), 7.47 (d, *J* = 1.9 Hz, 1H), 7.29 (d, *J* = 1.8 Hz, 1H), 4.09 (q, *J* = 7.0 Hz, 2H), 1.48 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101

MHz, CDCl₃) δ 195.21, 151.68, 148.54, 132.51, 127.19, 122.22, 79.80, 65.15, 14.59. HRMS (ESI) [M+H]⁺:m/z 292.978; Calculated mass for C₉H₉O₃ is 291.960.

2.1.3. General Synthetic Method for the Reductive-amination of 2-ethoxybenzaldehyde Derivatives

Mixture of 2-hydroxy-3-ethoxybenzaldehyde **1** (0.100 g, 0.602 mmol) or 5-bromo-3-ethoxy-2-hydroxybenzaldehyde **2** (0.100 g, 0.408 mmol) or 3-ethoxy-2-hydroxy-5-iodobenzaldehyde **3** (0.100 g, 0.342 mmol) and appropriate amine (0.632 mol, 1.05 eq.) in methanol (15 mL) was stirred for 18 hours before being reduced with sodium borohydride (0.04556 g, 1.20 mmol, 2 eq.) and stirred at room temperature for a further 4 hours. Subsequently, the reaction mixture was quenched with a saturated aqueous solution of ammonium chloride and extracted with ethyl acetate (3 x 30 mL). The combined organic fractions were dried with anhydrous sodium sulphate, the solvent was removed on a rotary evaporator and the resulting product was purified by flash silica gel column chromatography (5 – 30% ethyl acetate in hexane) to afford the appropriate product.

2.1.4. 3-Ethoxy-2-hydroxy-N-(phenyl)benzylamine (1a)

As a yellow-brown oil, 0.1324 g, 84%. ¹H NMR (400 MHz, CDCl₃) δ 7.23 – 7.13 (m, 2H), 6.92 – 6.86 (m, 1H), 6.79 (d, *J* = 4.8 Hz, 2H), 6.76 (dd, *J* = 7.3, 0.9 Hz, 1H), 6.72 (dd, *J* = 8.5, 0.9 Hz, 2H), 4.38 (s, 2H), 4.13 (q, *J* = 7.0 Hz, 2H), 1.45 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 147.73, 145.85, 144.02, 129.15, 124.38, 121.06, 119.49, 118.18, 113.77, 110.75, 64.47, 44.09, 14.89, 3417, 2978, 1460, 1253, 1053, 747, 600cm⁻¹. HRMS (ESI) [M+H]⁺:m/z 243.1366; Calculated mass for C₁₅H₁₇NO₂ is 242.130.

2.1.5. 5-Bromo-3-ethoxy-2-hydroxy-N-(phenyl)benzylamine

(**2a**) As a light orange solid crystals, 0.1030 g, 78%, mp 88-90 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.17 (dd, *J* = 8.4, 7.5 Hz, 2H), 7.02 (d, *J* = 2.1 Hz, 1H), 6.88 (d, *J* = 2.1 Hz, 1H), 6.75 (t, *J* = 7.3 Hz, 1H), 6.68 (d, *J* = 7.7 Hz, 2H), 4.33 (s, 2H), 4.07 (q, *J* = 7.0 Hz, 2H), 1.44 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 147.60, 146.53, 143.11, 129.22, 126.24, 123.35, 118.32, 113.97, 113.62, 111.32, 64.86, 43.68, 14.74. HRMS (ESI) [M+H]⁺:m/z 322.0440; Calculated mass for C₁₅H₁₆BrNO₂ is 321.040.

2.1.6. 3-Ethoxy-2-hydroxy-5-iodo-N-(phenyl)benzylamine(3a)

As a light brown solid, 0.1019 g, 81%, mp 78-81 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.19 (ddd, *J* = 8.5, 5.5, 1.8 Hz, 3H), 7.04 (d, *J* = 1.9 Hz, 1H), 6.76 (t, *J* = 7.3 Hz, 1H), 6.71 – 6.66 (m, 2H), 4.31 (s, 2H), 4.05 (q, *J* = 7.0 Hz, 2H), 1.44 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 147.61, 146.66, 143.99, 129.53, 129.18, 126.81, 119.58, 118.26, 113.59, 80.80, 64.80, 43.51, 14.73. Vmax (FTIR) 2968, 1488, 1273, 1078, 839, 772, 695, 576, 511 cm⁻¹. HRMS (ESI) [M+H]⁺:m/z 370.0337; Calculated mass for C₁₅H₁₆INO₂ is 369.020.

2.1.7. 3-Ethoxy-2-hydroxy-N-(benzyl)benzylamine (1b)

As a cream white solid, 0.1324 g, 88%, mp 76 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.45 – 7.16 (m, 5H), 6.85 (dd, *J* =

8.1, 1.3 Hz, 1H), 6.79 – 6.73 (m, 1H), 6.68 – 6.63 (m, 1H), 4.12 (q, *J* = 7.0 Hz, 2H), 4.02 (s, 2H), 3.85 (s, 2H), 1.51 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 147.30, 147.22, 138.23, 128.55, 128.35, 127.45, 122.68, 120.53, 118.64, 112.12, 64.10, 52.51, 51.33, 14.89. Vmax (FTIR) 3294, 2958, 1470, 1275, 1043, 836, 774, 734, 699, 605, 554, 481, 432 cm⁻¹. HRMS (ESI) [M+H]⁺:m/z 258.1482; Calculated mass for C₁₆H₁₉NO₂ is 257.140.

2.1.8. 5-Bromo-3-ethoxy-2-hydroxy-N-(benzyl)benzylamine (2b)

As a brown solid, 0.1198 g, 87%, mp 87-89 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.19 (m, 7H), 6.85 (d, *J* = 2.0 Hz, 1H), 6.69 (d, *J* = 1.9 Hz, 1H), 3.99 (q, *J* = 7.0 Hz, 2H), 3.88 (s, 2H), 3.74 (s, 2H), 1.41 (dd, *J* = 8.9, 5.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 147.97, 146.49, 137.76, 128.60, 128.32, 127.57, 123.79, 122.92, 115.12, 110.16, 64.39, 52.40, 50.82, 14.68. Vmax (FTIR) 3300, 2921, 1454, 1233, 1068, 884, 848, 820, 751, 698, 569 cm⁻¹. HRMS (ESI) [M+H]⁺:m/z 335.0613; Calculated mass for C₁₆H₁₈BrNO₂ is 334.050.

2.1.9. 3-Ethoxy-2-hydroxy-5-iodo-N-(benzyl)benzylamine (3b)

As a brown solid, 0.1111 g, 85%, mp 71-72 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.36 – 7.26 (m, 5H), 7.04 (d, *J* = 1.8 Hz, 1H), 6.92 (d, *J* = 1.8 Hz, 1H), 4.03 (q, *J* = 7.0 Hz, 2H), 3.92 (s, 2H), 3.79 (s, 2H), 1.44 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 148.17, 147.43, 137.76, 129.13, 128.64, 128.35, 127.61, 124.52, 120.87, 79.62, 64.43, 52.44, 50.63, 14.73. Vmax (FTIR) 3301, 2926, 1454, 1233, 1068, 821, 754, 700, 566, 484 cm⁻¹. HRMS (ESI) [M+H]⁺:m/z 384.0457; Calculated mass for C₁₆H₁₈INO₂ is 383.040.

2.1.10. 3-Ethoxy-2-hydroxy-N-(2-picolyl)benzylamine (1c)

As a light brown solid, 0.1302 g, 84%, mp 67-70 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, *J* = 4.7 Hz, 1H), 7.57 (td, *J* = 7.7, 1.7 Hz, 1H), 7.16 (d, *J* = 7.8 Hz, 1H), 7.11 (dt, *J* = 11.9, 6.0 Hz, 1H), 6.78 – 6.72 (m, 1H), 6.66 (t, *J* = 7.8 Hz, 1H), 6.55 (d, *J* = 7.5 Hz, 1H), 4.02 (q, *J* = 7.0 Hz, 2H), 3.93 (s, 2H), 3.85 (s, 2H), 1.40 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 157.66, 149.03, 147.10, 146.99, 136.43, 122.78, 122.43, 122.09, 120.52, 118.40, 111.95, 63.90, 52.88, 51.14, 14.69. Vmax (FTIR) 3055, 2975, 2923, 1432, 1232, 1068, 884, 826, 762, 725, 630, 563 cm⁻¹. HRMS (ESI) [M+H]⁺:m/z 259.1435; Calculated mass for C₁₅H₁₈N₂O₂ is 258.140.

2.1.11. 3-Ethoxy-2-hydroxy-5-iodo-N-(2-picolyl)benzylamine (3c)

As a brown-yellow solid, 0.1099 g, 83%, mp 67-69 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, *J* = 4.4 Hz, 1H), 7.60 – 7.52 (m, 1H), 7.18 – 7.07 (m, 3H), 6.97 (d, *J* = 1.7 Hz, 1H), 6.85 (s, 1H), 3.96 (q, *J* = 7.0 Hz, 2H), 3.87 (s, 2H), 3.83 (s, 2H), 1.37 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 149.01, 147.94, 147.25, 136.47, 136.41, 129.11, 122.46, 122.19, 122.12, 120.63, 79.39, 64.21, 52.60, 14.55. Vmax (FTIR) 3186, 2976, 1465, 1233, 1070, 886, 818, 759, 651, 568, 406cm⁻¹. HRMS (ESI) [M+H]⁺:m/z 385.0414; Calculated mass for C₁₅H₁₇INO₂ is 384.030.

2.1.12. 3-Ethoxy-2-hydroxy-N-(2-fluorophenyl)benzylamine (1d)

As a brown solid crystals, 0.1384 g, 88%, mp 89-91 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.01 – 6.93 (m, 2H), 6.92 – 6.86 (m, 1H), 6.83 – 6.77 (m, 3H), 6.67 – 6.59 (m, 1H), 4.41 (s, 2H), 4.11 (q, *J* = 7.0 Hz, 1H), 1.45 (t, *J* = 7.0 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 152.94, 150.57, 145.73, 143.81, 136.54, 136.42, 124.51, 124.47, 124.23, 120.89, 119.52, 116.98, 116.91, 114.40, 114.22, 112.84, 112.80, 64.50, 43.04, 14.88. Vmax (FTIR) 3429, 2923, 1463, 1268, 1048, 855, 747, 730, 519, 481, 455 cm⁻¹. HRMS (ESI) [M+H⁺]:*m/z* 262.1239; Calculated mass for C₁₅H₁₆FNO₂ is 261.120.

2.1.13. 5-Bromo-3-ethoxy-2-hydroxy-N-(2-fluorophenyl)benzylamine (2c)

As a cream white solid, 0.1198 g, 86%, mp 111-112 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.02 (d, *J* = 2.1 Hz, 1H), 7.00 – 6.93 (m, 2H), 6.89 (d, *J* = 2.2 Hz, 1H), 6.73 (dd, *J* = 12.5, 4.4 Hz, 1H), 6.69 – 6.61 (m, 1H), 4.37 (s, 2H), 4.08 (q, *J* = 7.0 Hz, 2H), 1.45 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 153.02, 150.65, 146.40, 142.92, 125.82, 124.60, 124.57, 123.34, 117.60, 117.54, 114.57, 114.39, 113.99, 113.02, 111.41, 64.92, 42.86, 14.75. Vmax (FTIR) 3518, 2952, 1483, 1275, 1052, 745, 623, 512, 485, 456 cm⁻¹. HRMS (ESI) [M+H⁺]:*m/z* 340.0344; Calculated mass for C₁₅H₁₅BrFNO₂ is 339.03.

2.1.14. 3-Ethoxy-2-hydroxy-5-iodo-N-(2-fluorophenyl)benzylamine (3d)

As an orange solid crystals, 0.1324 g, 86%, mp 109-111 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.21 (d, *J* = 1.9 Hz, 1H), 7.04 (d, *J* = 1.9 Hz, 1H), 7.00 – 6.93 (m, 2H), 6.77 – 6.71 (m, 1H), 6.69 – 6.62 (m, 1H), 4.34 (s, 2H), 4.07 (q, *J* = 7.0 Hz, 2H), 1.44 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 153.04, 150.67, 146.55, 143.83, 135.87, 135.75, 129.61, 126.33, 124.60, 124.57, 119.67, 117.69, 117.62, 114.58, 114.39, 113.12, 80.86, 64.91, 42.78, 14.77. Vmax (FTIR) 3452, 1618, 1458, 1272, 1221, 1085, 824, 745, 511 cm⁻¹. HRMS (ESI) [M+H⁺]:*m/z* 388.0216; Calculated mass for C₁₅H₁₅FINO₂ is 387.010.

2.1.15. 3-Ethoxy-2-hydroxy-N-(2-iodophenyl)benzylamine (1e)

As a brown oil, 0.1989 g, 85%. ¹H NMR (400 MHz, CDCl₃) δ 7.58 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.08 (ddt, *J* = 9.5, 3.6, 1.8 Hz, 1H), 6.82 – 6.76 (m, 1H), 6.73 – 6.70 (m, 2H), 6.56 (dd, *J* = 8.2, 1.4 Hz, 1H), 6.36 (td, *J* = 7.6, 1.4 Hz, 1H), 4.36 (s, 2H), 4.03 (q, *J* = 7.0 Hz, 2H), 1.38 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 147.12, 145.67, 143.67, 138.92, 129.35, 123.98, 120.60, 119.55, 118.83, 111.24, 110.53, 85.59, 64.50, 43.33, 14.91. Vmax (FTIR) 3400, 2928, 1470, 1262, 1054, 857, 736, 644, 416 cm⁻¹. HRMS (ESI) [M+H⁺]:*m/z* 370.1025; Calculated mass for C₁₅H₁₆IINO₂ is 369,200.

2.1.16. 5-Bromo-3-ethoxy-2-hydroxy-N-(2-iodophenyl) benzylamine (2d)

As an orange-yellow solid, 0.1639 g, 90%, mp 72-75 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.19 – 7.14 (m, 1H), 7.00 (d, *J* = 2.0 Hz, 1H), 6.89 (d, *J* = 2.0

Hz, 1H), 6.58 (d, *J* = 8.2 Hz, 1H), 6.49 – 6.43 (m, 1H), 4.39 (s, 2H), 4.08 (q, *J* = 7.0 Hz, 2H), 1.45 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 146.74, 146.33, 142.77, 139.00, 129.42, 125.68, 123.09, 119.25, 113.88, 111.45, 111.29, 85.71, 64.90, 43.17, 14.76. Vmax (FTIR) 3421, 2922, 1486, 1230, 1090, 819, 744, 561, 419 cm⁻¹. HRMS (ESI) [M+H⁺]:*m/z* 447.9410; Calculated mass for C₁₅H₁₅BrINO₂ is 446.93.

2.1.17. 3-Ethoxy-2-hydroxy-5-iodo-N-(2-iodophenyl)benzylamine (3e)

As a brown solid, 0.1501 g, 89%, mp 78-80 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.18 (d, *J* = 1.6 Hz, 1H), 7.17 – 7.14 (m, 1H), 7.04 (d, *J* = 1.8 Hz, 1H), 6.59 (dd, *J* = 8.2, 1.2 Hz, 1H), 6.46 (td, *J* = 7.7, 1.4 Hz, 1H), 4.36 (s, 2H), 4.07 (q, *J* = 7.0 Hz, 2H), 1.44 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 146.82, 146.49, 143.69, 138.99, 129.42, 129.35, 126.28, 119.54, 119.20, 111.25, 85.72, 80.92, 64.89, 43.06, 14.78. Vmax (FTIR) 3403, 2923, 1460, 1245, 1055, 1003, 895, 839, 735, 640, 575, 540, 427 cm⁻¹. HRMS (ESI) [M+H⁺]:*m/z* 495.9275; Calculated mass for C₁₅H₁₅I₂NO₂ is 494.920.

2.1.18. 3-Ethoxy-2-hydroxy-N-(2-methoxyphenyl)benzylamine (1f)

As a brown solid, 0.1462 g, 89%, mp 102-104 °C. ¹H NMR (400 MHz, CDCl₃) δ 6.90 – 6.84 (m, 3H), 6.80 – 6.77 (m, 2H), 6.64 (m, 2H), 4.32 (s, 2H), 4.13 (q, *J* = 7.0 Hz, 2H), 1.47 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 157.42, 155.08, 145.89, 144.06, 124.20, 121.05, 119.54, 115.69, 115.47, 114.74, 114.67, 110.83, 64.49, 44.81, 14.89. Vmax (FTIR) 3371, 2987, 2923, 1467, 1253, 1059, 1005, 817, 763, 725, 503, 435 cm⁻¹. HRMS (ESI) [M+H⁺]:*m/z* 274.2379; Calculated mass for C₁₆H₁₉NO₃ is 273.140.

2.1.19. 5-Bromo-3-ethoxy-2-hydroxy-N-(2-methoxyphenyl) benzylamine (2e)

As a brown-yellow solid, 0.1302 g, 91%, mp 105-106 °C. ¹H NMR (400 MHz, CDCl₃) δ 6.99 (d, *J* = 2.2 Hz, 1H), 6.91 – 6.83 (m, 3H), 6.64 – 6.56 (m, 2H), 4.28 (s, 2H), 4.06 (q, *J* = 7.0 Hz, 2H), 1.44 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 157.47, 155.12, 146.56, 143.82, 143.80, 143.13, 125.96, 123.31, 115.76, 115.53, 114.64, 114.57, 114.01, 111.33, 64.85, 44.35, 14.71. Vmax (FTIR) 3292, 2958, 2921, 1483, 1464, 1203, 1105, 1064, 824, 757, 727, 573, 509, 409 cm⁻¹. HRMS (ESI) [M+H⁺]:*m/z* 353.1584; Calculated mass for C₁₆H₁₈BrNO₃ is 352.050.

2.1.20. 3-Ethoxy-2-hydroxy-5-iodo-N-(2-methoxyphenyl)benzylamine (3f)

As a yellow solid, 0.1157 g, 85%, mp 111-113 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.20 (d, *J* = 1.9 Hz, 1H), 7.04 (d, *J* = 1.9 Hz, 1H), 6.88 – 6.81 (m, 1H), 6.81 – 6.76 (m, 2H), 6.76 – 6.69 (m, 1H), 6.66 (dt, *J* = 7.2, 3.6 Hz, 1H), 4.33 (s, 2H), 4.06 (q, *J* = 7.0 Hz, 2H), 3.84 (s, 3H), 1.46 – 1.41 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 147.34, 146.76, 144.22, 137.28, 129.46, 126.82, 121.20, 119.68, 117.83, 111.29, 109.46, 80.77, 64.81, 55.40, 43.52, 14.77. Vmax (FTIR) 3420, 1443, 1265, 1082, 1048, 866, 848, 780, 740, 571, 457 cm⁻¹.

HRMS (ESI) [M+H⁺]:m/z 400.0447; Calculated mass for C₁₆H₁₈INO₃ is 399.030.

2.1.21. 3-Ethoxy-2-hydroxy-N-(4-fluorophenyl)benzylamine (1g)

As a cream white solid, 0.1325 g, 84%, mp 68-70 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.28 (s, 1H), 6.95 – 6.87 (m, 3H), 6.84 – 6.80 (m, 2H), 6.70 – 6.63 (m, 2H), 4.36 (s, 2H), 4.14 (q, *J* = 7.0 Hz, 2H), 1.48 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 156.23 (d, *J* = 235.4 Hz), 145.97, 144.34, 144.32, 144.12, 124.40, 121.08, 119.60, 115.74, 115.52, 114.66, 114.59, 110.87, 64.55, 44.79, 14.95. V_{max} (FTIR) 3436, 2924, 1446, 1252, 1057, 815, 762, 725, 507, 447 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 262.1239; Calculated mass for C₁₅H₁₆FNO₂ is 261.120.

2.1.22. 5-Bromo-3-ethoxy-2-hydroxy-N-(4-fluorophenyl)benzylamine (2f)

As a yellow solid, 0.1129 g, 81%, mp 105-107 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.00 (d, *J* = 2.2 Hz, 1H), 6.91 – 6.84 (m, 3H), 6.65 – 6.58 (m, 2H), 4.29 (s, 2H), 4.07 (q, *J* = 7.0 Hz, 2H), 1.47 – 1.42 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 157.57, 155.22, 146.57, 143.16, 125.87, 123.38, 115.80, 115.57, 114.78, 114.71, 114.07, 111.36, 64.88, 44.44, 14.74. V_{max} (FTIR) 3292, 2920, 1241, 1066, 829, 762, 728, 580, 509 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 340.0337; Calculated mass for C₁₅H₁₅BrFNO₂ is 339.03.

2.1.23. 3-Ethoxy-2-hydroxy-5-iodo-N-(4-fluorophenyl)benzylamine (3g)

As a yellow solid, 0.1100 g, 83%, mp 79-81 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.18 (d, *J* = 1.9 Hz, 1H), 7.03 (d, *J* = 1.9 Hz, 1H), 6.89 (d, *J* = 8.8 Hz, 2H), 6.67 – 6.58 (m, 2H), 4.26 (s, 2H), 4.06 (q, *J* = 7.0 Hz, 2H), 1.43 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 157.66, 155.31, 146.72, 144.08, 143.49, 129.65, 126.31, 119.75, 115.80, 115.58, 114.97, 114.90, 80.83, 64.86, 44.40, 14.76. V_{max} (FTIR) 3377, 2922, 1466, 1200, 1094, 817, 793, 757, 729, 575, 499, 444cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 388.0201; Calculated mass for C₁₅H₁₅I₂FNO₂ is 387.010.

2.1.24. 3-Ethoxy-2-hydroxy-N-(4-iodophenyl)benzylamine (1h)

As a limestone brown solid, 0.2001 g, 90%, mp 93-95 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, *J* = 8.8 Hz, 2H), 6.88 – 6.81 (m, 2H), 6.80 – 6.72 (m, 2H), 6.52 (d, *J* = 8.8 Hz, 2H), 4.33 (s, 2H), 4.09 (q, *J* = 7.0 Hz, 2H), 1.44 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 145.75, 143.83, 137.76, 121.17, 119.62, 116.46, 110.85, 77.20, 64.53, 43.96, 14.89. V_{max} (FTIR) 3410, 2979, 1466, 1273, 1054, 847, 808, 762, 730, 558, 494 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 370.0305; Calculated mass for C₁₅H₁₆INO₂ is 370.200.

2.1.25. 5-Bromo-3-ethoxy-2-hydroxy-N-(4-iodophenyl) benzylamine (2g)

As a grey-green solid, 0.1721 g, 94%, mp 112-114 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, *J* = 8.0, 2H), 6.98 (d, *J* = 2.1 Hz, 1H), 6.87 (d, *J* = 2.2 Hz, 1H), 6.47 – 6.40 (m, 2H), 4.28

(s, 2H), 4.07 (q, *J* = 7.0 Hz, 2H), 1.44 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 147.19, 146.36, 142.77, 137.73, 125.81, 123.25, 115.54, 113.90, 111.40, 78.80, 64.90, 42.89, 14.74. V_{max} (FTIR) 3488, 1488, 1298, 1049, 813, 785, 577, 511, 511, 483 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 447.9413; Calculated mass for C₁₅H₁₅BrINO₂ is 446.93.

2.1.26. 3-Ethoxy-2-hydroxy-5-iodo-N-(4-iodophenyl)benzylamine (3h)

As a white solid, 0.1330 g, 79%, mp 143-145 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, *J* = 8.0 Hz, 2H), 7.17 (d, *J* = 1.8 Hz, 1H), 7.02 (d, *J* = 1.9 Hz, 1H), 6.45 (d, *J* = 8.0 Hz, 2H), 4.26 (s, 2H), 4.06 (q, *J* = 7.0 Hz, 2H), 1.43 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 146.81, 146.54, 143.75, 137.78, 129.61, 126.11, 119.65, 115.90, 80.88, 79.35, 64.91, 43.03, 14.76. V_{max} (FTIR) 3487, 1471, 1262, 1047, 812, 780, 563, 486 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 495.9283; Calculated mass for C₁₅H₁₅I₂NO₂ is 494.920.

2.1.27. 3-Ethoxy-2-hydroxy-N-(4-methoxyphenyl)benzylamine (1i)

As a dark brown solid, 0.1402 g, 85%, mp 82-85 °C. ¹H NMR (400 MHz, CDCl₃) δ 6.86 – 6.84 (m, 1H), 6.80 – 6.75 (m, 4H), 6.72 – 6.67 (m, 2H), 4.33 (s, 2H), 4.09 (q, *J* = 7.0 Hz, 2H), 3.74 (s, 3H), 1.44 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 152.76, 146.09, 144.47, 141.79, 120.93, 119.39, 115.45, 114.65, 110.97, 64.38, 55.63, 45.81, 14.85. V_{max} (FTIR) 3383, 2923, 1464, 1221, 1124, 1032, 816, 765, 720, 637, 518 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 274.1428; Calculated mass for C₁₆H₁₉NO₃ is 273.140.

2.1.28. 5-Bromo-3-ethoxy-2-hydroxy-N-(4-methoxyphenyl) benzylamine (2h)

As a brown-yellow solid, 0.1290 g, 90%, mp 82-84 °C. ¹H NMR (400 MHz, CDCl₃) δ 6.98 (d, *J* = 2.2 Hz, 1H), 6.88 (d, *J* = 2.2 Hz, 1H), 6.79 – 6.74 (m, 2H), 6.70 – 6.64 (m, 2H), 4.28 (s, 2H), 4.05 (q, *J* = 7.0 Hz, 2H), 3.73 (s, 3H), 1.44 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 153.08, 146.83, 143.68, 141.21, 125.99, 123.29, 115.66, 114.73, 114.21, 111.18, 64.77, 55.65, 45.68, 14.71. V_{max} (FTIR) 3410, 2921, 1488, 1231, 1050, 1033, 820, 705, 578, 508 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 352.0540; Calculated mass for C₁₆H₁₈BrNO₃ is 351.050.

2.1.29. 3-Ethoxy-2-hydroxy-5-iodo-N-(4-methoxyphenyl)benzylamine (3i)

As a brown-yellow solid, 0.1199 g, 88%, mp 78-81 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.16 (d, *J* = 1.9 Hz, 1H), 7.03 (d, *J* = 1.9 Hz, 1H), 6.77 (d, *J* = 8.0 Hz, 2H), 6.69 (d, *J* = 8.0 Hz, 2H), 4.27 (s, 2H), 4.05 (q, *J* = 7.0 Hz, 2H), 3.73 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 153.30, 147.01, 144.63, 140.88, 129.60, 126.38, 119.97, 115.94, 114.75, 80.72, 64.79, 55.67, 45.71, 14.76. V_{max} (FTIR) 3507, 2965, 1466, 1218, 1053, 1031, 818, 522, 423 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 400.0397; Calculated mass for C₁₆H₁₈INO₃ is 399.030.

2.1.30. 3-Ethoxy-2-hydroxy-N-(2-bromo-4-methylphenyl)benzylamine (1j)

As a brown solid, 0.2032 g, 95%, mp 67-69 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, *J* = 1.4 Hz, 1H), 7.00 – 6.95 (m,

1H), 6.90 (dt, $J = 6.5, 3.3$ Hz, 1H), 6.84 – 6.80 (m, 2H), 6.66 (d, $J = 8.2$ Hz, 1H), 4.45 (s, 2H), 4.14 (q, $J = 7.0$ Hz, 2H), 2.24 (s, 3H), 1.49 (t, $J = 7.0$ Hz, 3H). 13C NMR (101 MHz, CDCl₃) δ 145.72, 143.78, 142.46, 132.67, 128.94, 127.78, 124.15, 120.67, 119.52, 112.21, 110.58, 110.03, 64.49, 43.50, 20.01, 14.90. Vmax (FTIR) 3534, 2921, 2852, 1463, 1273, 1058, 861, 800, 722, 549, 424 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 336.0570; Calculated mass for C₁₆H₁₈BrNO₂ is 335.050.

2.1.31. 3-Ethoxy-2-hydroxy-5-iodo-N-(2-bromo-4-methylphenyl) benzylamine (3j)

As a peach solid, 2.21 g, 98%, mp 99-101 °C. 1H NMR (400 MHz, CDCl₃) δ 7.26 (d, $J = 1.4$ Hz, 1H), 7.18 (d, $J = 1.9$ Hz, 1H), 7.03 (d, $J = 1.9$ Hz, 1H), 6.94 (dd, $J = 8.2, 1.4$ Hz, 1H), 6.59 (d, $J = 8.2$ Hz, 1H), 4.34 (s, 2H), 4.06 (q, $J = 7.0$ Hz, 2H), 2.21 (s, 3H), 1.44 (t, $J = 7.0$ Hz, 3H). Vmax (FTIR) 3404, 1471, 1273, 1052, 860, 805, 777, 719, 673, 559, 526 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 447.2945; Calculated mass for C₁₅H₁₅BrINO₂ is 446.930.

2.1.32. Methyl3-bromo-4-((3-ethoxy-2-hydroxybenzyl)amino) benzoate (1k)

As a yellow solid, 0.2020 g, 89%, mp 89-91 °C. 1H NMR (400 MHz, MeOD) δ 7.99 (d, $J = 1.9$ Hz, 1H), 7.71 – 7.67 (m, 1H), 6.91 (dd, $J = 7.4, 1.7$ Hz, 1H), 6.84 – 6.73 (m, 4H), 4.94 (s, 6H), 4.68 (s, 2H), 4.05 (q, $J = 7.0$ Hz, 3H), 3.82 (s, 3H), 1.40 (t, $J = 7.0$ Hz, 4H). 13C NMR (101 MHz, MeOD) δ 168.11, 151.69, 147.80, 145.50, 135.63, 131.42, 128.84, 121.59, 120.38, 120.14, 115.30, 112.89, 108.04, 65.78, 60.87, 52.57, 15.42. Vmax (FTIR) 3462, 2982, 1689, 1471, 1247, 1114, 1070, 829, 763, 737, 632, 436 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 380.0502; Calculated mass for C₁₇H₁₈BrNO₄ is 379.040.

2.1.33. 3-Ethoxy-2-hydroxy-N-(5-Chloro-2-iodophenyl)benzylamine (1l)

As a peach solid, 0.2034 g, 83%, mp 68-70 °C. 1H NMR (400 MHz, CDCl₃) δ 7.53 (d, $J = 8.3$ Hz, 1H), 6.85 (dt, $J = 9.5, 3.9$ Hz, 1H), 6.82 – 6.79 (m, 2H), 6.63 (d, $J = 2.3$ Hz, 1H), 6.43 (dd, $J = 8.3, 2.3$ Hz, 1H), 4.39 (s, 2H), 4.12 (q, $J = 7.0$ Hz, 2H), 1.45 (t, $J = 7.0$ Hz, 3H). 13C NMR (101 MHz, CDCl₃) δ 148.02, 145.69, 143.69, 139.38, 135.49, 123.26, 120.69, 119.69, 118.63, 111.02, 110.73, 82.37, 64.56, 43.22, 14.91. Vmax (FTIR) 3478, 2954, 1482, 1220, 1080, 831, 765, 725, 644, 505, 435 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 404.9954; Calculated mass for C₁₅H₁₅ClINO₂ is 402.980.

2.1.34. 5-Bromo-3-ethoxy-2-hydroxy-N-(5-chloro-2-iodophenyl) benzylamine (2i)

As a brown solid, 0.1679 g, 85%, mp 96-99 °C. 1H NMR (400 MHz, CDCl₃) δ 7.57 – 7.51 (m, 1H), 6.97 (d, $J = 2.1$ Hz, 1H), 6.90 (d, $J = 2.1$ Hz, 1H), 6.54 (d, $J = 2.3$ Hz, 1H), 6.44 (dd, $J = 8.3, 2.3$ Hz, 1H), 4.35 (s, 2H), 4.13 – 4.05 (q, $J = 7.0$ Hz, 2H), 1.45 (t, $J = 7.0$ Hz, 3H). 13C NMR (101 MHz, CDCl₃) δ 147.81, 146.32, 142.71, 139.44, 135.52, 125.08, 123.02, 118.85, 114.04, 111.54, 110.82, 82.36, 64.97, 42.72, 14.75. Vmax (FTIR) 3377, 2921, 1455, 1280, 1080, 1007, 822, 786, 721, 576, 429 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 482.8921;

Calculated mass for C₁₅H₁₄BrClINO₂ is 480.890.

2.1.35. 3-Ethoxy-2-hydroxy-5-iodo-N-(5-chloro-2-iodophenyl) benzylamine (3k)

As a yellow solid, 0.1502 g, 83%, mp 70-73 °C. 1H NMR (400 MHz, CDCl₃) δ 7.55 – 7.48 (m, 2H), 7.16 (d, $J = 1.8$ Hz, 1H), 7.05 (d, $J = 1.8$ Hz, 1H), 6.72 (d, $J = 2.3$ Hz, 1H), 6.54 (d, $J = 2.3$ Hz, 1H), 6.45 (td, $J = 8.1, 2.3$ Hz, 2H), 4.32 (s, 2H), 4.08 (q, $J = 7.0$ Hz, 2H), 1.45 (t, $J = 7.0$ Hz, 3H). 13C NMR (101 MHz, CDCl₃) δ 147.86, 146.48, 143.63, 139.60, 139.44, 135.52, 129.33, 125.67, 119.93, 119.69, 118.83, 114.20, 110.82, 82.37, 81.00, 80.98, 64.96, 42.61, 14.77. Vmax (FTIR) 3458, 2921, 1271, 1070, 838, 774, 734, 690, 646, 569, 492, 437 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 530.4001; Calculated mass for C₁₅H₁₄ClI₂NO₂ is 528.880.

2.1.36. 3-Ethoxy-2-hydroxy-N-(5-fluoro-2-iodophenyl) benzylamine (1m)

As a light brown solid, 0.1981 g, 85%, mp 74-76 °C. 1H NMR (400 MHz, CDCl₃) δ 7.54 (dt, $J = 8.7, 6.2$ Hz, 2H), 6.88 – 6.82 (m, 1H), 6.82 – 6.76 (m, 2H), 6.45 (dd, $J = 10.5, 2.8$ Hz, 1H), 6.36 (dd, $J = 11.7, 2.8$ Hz, 1H), 4.40 (s, 2H), 4.11 (q, $J = 7.0$ Hz, 2H), 1.45 (t, $J = 7.0$ Hz, 3H). 13C NMR (101 MHz, CDCl₃) δ 165.55, 165.14, 163.13, 162.71, 148.68, 148.57, 148.09, 147.98, 145.65, 143.60, 139.63, 139.53, 139.26, 139.16, 123.38, 120.55, 119.63, 110.61, 107.24, 107.01, 105.48, 105.26, 101.59, 101.34, 98.60, 98.33, 77.95, 77.92, 64.51, 43.02, 14.87. Vmax (FTIR) 3405, 2921, 1455, 1260, 1055, 856, 828, 763, 734, 588, 516, 438 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 388.0225; Calculated mass for C₁₅H₁₅FINO₂ is 387.010.

2.1.37. 5-Bromo-3-ethoxy-2-hydroxy-N-(5-fluoro-2-iodophenyl)benzylamine (2j)

As a yellow solid, 0.1601 g, 84%, mp 83-85 °C. 1H NMR (400 MHz, CDCl₃) δ 7.56 (dd, $J = 8.6, 6.3$ Hz, 1H), 6.97 (d, $J = 2.1$ Hz, 1H), 6.89 (d, $J = 2.2$ Hz, 1H), 6.29 (dd, $J = 11.6, 2.8$ Hz, 1H), 6.20 (ddd, $J = 11.8, 8.7, 3.9$ Hz, 1H), 4.35 (s, 2H), 4.08 (q, $J = 7.0$ Hz, 2H), 1.45 (t, $J = 7.0$ Hz, 3H). 13C NMR (101 MHz, CDCl₃) δ 165.54, 163.12, 148.37, 148.26, 146.30, 142.65, 139.37, 139.28, 125.13, 122.93, 113.95, 111.53, 105.84, 105.62, 98.60, 98.33, 78.00, 77.97, 64.94, 42.66, 14.73. Vmax (FTIR) 3476, 2922, 1453, 1269, 1091, 816, 775, 559, 464 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 467.9312; Calculated mass for C₁₅H₁₄BrFINO₂ is 466.091.

2.1.38. 3-Ethoxy-2-hydroxy-N-(3,5-dichlorophenyl)benzylamine (1n)

As a white solid, 0.1632 g, 87%, mp 88-91 °C. 1H NMR (400 MHz, CDCl₃) δ 6.85 – 6.81 (m, 1H), 6.80 – 6.76 (m, 2H), 6.64 (t, $J = 1.7$ Hz, 1H), 6.52 (d, $J = 1.7$ Hz, 2H), 4.30 (s, 2H), 4.11 (q, $J = 7.0$ Hz, 2H), 1.45 (t, $J = 7.0$ Hz, 3H). 13C NMR (101 MHz, CDCl₃) δ 149.68, 145.72, 143.69, 135.30, 123.51, 121.00, 119.69, 117.15, 111.30, 110.80, 64.57, 43.04, 14.89. Vmax (FTIR) 3445, 2980, 1468, 1271, 1058, 796, 737, 667, 630, 562, 499, 476, 435 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 312.0563; Calculated mass for C₁₅H₁₅Cl₂NO₂ is 311.050.

2.1.39. 5-Bromo-3-ethoxy-2-hydroxy-N-(3,5-dichlorophenyl) benzylamine (2k)

As a cream white solid, 0.1413 g, 89%, mp 121-123 °C. ¹H NMR (400 MHz, CDCl₃) δ 6.98 (d, *J* = 2.1 Hz, 1H), 6.89 (d, *J* = 2.2 Hz, 1H), 6.69 (t, *J* = 1.7 Hz, 1H), 6.53 (d, *J* = 1.7 Hz, 2H), 4.27 (s, 2H), 4.09 (q, *J* = 7.0 Hz, 2H), 1.45 (dd, *J* = 8.8, 5.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 146.37, 142.77, 135.43, 124.93, 123.34, 117.96, 114.16, 111.69, 111.52, 65.00, 42.76, 14.74. V_{max} (FTIR) 3426, 2923, 1456, 1274, 1068, 892, 821, 796, 667, 582, 496, 476 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 389.9667; Calculated mass for C₁₅H₁₄BrCl₂NO₂ is 388.960.

2.1.40. 3-Ethoxy-2-hydroxy-5-iodo-N-(3,5-dichlorophenyl) benzylamine (3l)

As a cream white solid, 0.1301 g, 86%, mp 108-110 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.15 (d, *J* = 1.9 Hz, 1H), 7.04 (d, *J* = 1.9 Hz, 1H), 6.66 (t, *J* = 1.7 Hz, 1H), 6.48 (d, *J* = 1.7 Hz, 2H), 4.24 (s, 2H), 4.06 (q, *J* = 7.0 Hz, 2H), 1.44 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 149.37, 146.46, 143.56, 135.33, 129.46, 125.80, 119.65, 117.37, 111.20, 80.95, 64.94, 42.25, 14.74. V_{max} (FTIR) 3370, 2919, 1442, 1262,

1102, 1055, 804, 667, 510, 463 cm⁻¹. HRMS (ESI) [M+H⁺]:m/z 400.3279; Calculated mass for C₁₅H₁₄Cl₂INO₂ is 399.030.

3. RESULTS AND DISCUSSIONS

3.1. Chemistry

To access the compounds with antitubercular properties, 3-ethoxysalicylaldehyde **1** served as the starting point of the investigations. The investigation started by iodinating the starting material using N-iodosuccinimide (NIS) according to the reported synthetic method. This method was also used for the bromination of the starting material using N-bromosuccinimide (NBS) resulting in the formation of products **2** and **3**, respectively (Scheme 1) [33]. Reductive amination is a very useful synthetic method that was used to access pharmaceutical drugs used in the treatment of various diseases such as cancer, diabetes, fungal infections and many more [34]. Compounds **1** – **3** were treated with various aromatic amines under reductive amination reaction conditions using sodium borohydride in methanol to yield benzylamine derivatives as shown in Scheme. (1) [34].




Fig. (1). Recent tuberculosis drugs.





Fig. (2). Approved drugs containing benzylamine.



Scheme (1). Reagents and conditions: (i) NIS and ACN, (ii) NBS and ACN, (iii) Primary amines, NaBH₄ and MeOH.

Compounds **1a-n** were synthesised by treating 3-ethoxysalicylaldehyde **1** with various aromatic amines and were obtained in good to excellent yields. The ¹H NMR spectra of the compounds showed the disappearance of the aldehyde signal around 10 ppm and the appearance of the methylene signals ranging from 3.93 – 4.68 ppm in addition to other proton signals from the aromatic amines. To supplement the ¹H NMR spectroscopy, the ¹³C NMR spectra were recorded. The ¹³C NMR spectra of **1a-n** showed the disappearance of the aldehyde signal around 196 ppm and the appearance of the methylene signals in the region of 43.04 – 52.57 ppm. The same aromatic amines used in the synthesis of compounds **1a-n** were also used for the construction of compounds **2a-k** and **3a-l** and thus displayed similar NMR spectroscopic characteristics. For example, in the case of compounds **2a-k** ¹H NMR spectra, methylene signals appeared in the region of 3.88 – 4.39 ppm while compounds **3a-l** showed methylene signals ranging from 3.83 ppm to 4.36 ppm. The ¹³C NMR spectra signals of the methylene group appeared between 42.66 and 52.40 ppm for compounds **2a-k** and between 42.25 and 52.60 ppm for compounds **3a-l**. The successful synthesis of all the compounds was confirmed by both ¹H and ¹³C NMR, IR and mass spectroscopy.

3.2. Biological Evaluation

All the synthesised compounds were evaluated for their biological activity against *Mycobacterium tuberculosis* (*Mtb*) H37RV strain. The biological assays were performed following a broth dilution method in 7H9_ADC_GLU_TW (7 days) and rifampicin was used as a positive control [35]. The results for the *in vitro* biological assays are displayed in Table 1. The biological assay results in Table 1 indicate that all compounds possessed activity against *Mycobacterium tuberculosis* with MIC₉₀ values ranging from 20.04 (most active) – > 125 μM (least active). Only one compound, **2f** was considered ineffective with an MIC₉₀ value >125 μM. Other compounds in this series exhibited better activity with MIC₉₀ values of < 30 μM. The most active compounds in this series, **2c** and **2e** exhibited MIC₉₀ values of 20.04 μM representing the most

active compounds for 2-fluorophenyl and 2-methoxyphenyl substituents, respectively.

When phenyl, benzyl, 2-picolyl and 2-iodophenyl were used as substituents, the most active compounds were **2a** (22.26 μM), **2b** (20.59 μM), **1c** (20.44 μM) and **3e** (20.29 μM), respectively. The use of *ortho*-substituted phenyl reagents has produced some of the most active compounds in the series while the use of *para*-substituted phenyl reagents produced compounds with reduced activity against *Mycobacterium tuberculosis*. For example, **2f** with 4-fluorophenyl substituent was inactive, **2g** with 4-iodophenyl substituent exhibited an activity of 20.39 μM while 4-methoxyphenyl (**3i**) had an activity of 21.89 μM. The reduced activity against *Mtb* was further observed when some disubstituted phenyl reagents were used. Compound **3j** displayed an activity of 21.54 μM, compound **1k** showed an activity of 21.21 μM and compound **3k** had the best activity at 21.84 μM. These MIC₉₀ values are slightly lower than those obtained for *ortho* and *para* substituted phenyl derivatives. Notably, 5-fluoro-2-iodophenyl and 3,5-dichlorophenyl substituents displayed MIC₉₀ values comparable to those of *ortho* substituted phenyl substituents. The most active compounds were **3i** (20.59 μM), followed by compound **1m** (20.64 μM) and lastly compound **1n** (20.67 μM).

In addition to the biological assays against *Mycobacterium tuberculosis*, cytotoxicity assays were also performed for all the compounds against Chinese Hamster Ovarian (CHO) cells to determine the concentration at which these compounds are likely to be toxic. Quantitative assessment of toxic activity *in vitro* was determined *via* the MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide] assay with emetine used as a standard [36]. The test compounds were largely non-toxic to CHO cells up to the highest concentration evaluated of 50 μM. Only two compounds, **3c** (12.45 μM) and **3h** (8.80 μM) showed moderate activity against the cells, with three other compounds (**3d**, 47.28 μM; **3i**, 44.98 μM and **3j**, 48.00 μM) showing low levels of toxicity. Interestingly, all the compounds showing weak to moderate activity against CHO cells contain iodo

substituent at position 5 of the benzylamine. However, not all compounds containing 5-iodo substituent displayed toxicity towards CHO cells, indicating that the whole structure of the compound is likely responsible for the activity observed.

3.3. Structure-activity Relationship and ADMET Predictions

The effect of substituents on the activity and cytotoxicity of the synthesised compounds was examined. Compounds containing 5-bromo substituent displayed the best activity against *Mycobacterium tuberculosis*. Notably, the activity of these compounds also depended on the type of substituents in the phenyl group. For example, ortho-substituted phenyl-containing compounds (**2c**, **2e**) were the most active against *Mtb* with the exception of **2d** which showed reduced activity. Although compounds containing 5-bromo substituent continued their activity against *Mtb* (**2a**, **2b**, **2g**), the only inactive compound in this study **2f** with 4-fluorophenyl belonged to the 5-bromo substituent series. Compounds containing 5-iodo substituent displayed slightly reduced activity that largely depended on the substituents in the phenyl group. For example, compounds with 2-iodophenyl (**3e**), 4-fluorophenyl (**3g**), 4-methoxyphenyl (**3i**), 5-chloro-2-iodophenyl (**3k**) and 3,5-dichlorophenyl (**3l**) were the more active against *Mtb* in comparison to compounds containing no substituent (**1e-n**) and other 5-bromo substituted benzylamine derivatives (**2e-k**). Unfortunately, the series of compounds containing 5-iodo substituent produced the only compounds in

this study that showed activity against CHO cells (**3c**, **3d**, **3h**, **3i** and **3j**).

Physicochemical properties (Adsorption, Distribution, Metabolism, Excretion and Toxicity (ADMET)) of the synthesised compounds were analysed using the online prediction software ADMETlab 2.0 [37, 38]. These physicochemical predictions will help in understanding the behaviour of the synthesised compounds after consumption and the results are displayed in Table 2. Most of the compounds in this synthetic series (Table 2) showed poor LogS values with the exception of compounds **1a-d**, **1f**, **1g**, **1i**, **2a**, **2b**, **2f**, **2g**, **3b**, and **3c** while only three compounds (**1b**, **1c**, and **3c**) possessed favourable LogP values. Additionally, only five compounds (**1b**, **1c**, **3c**, **3h**, and **3l**) possessed LogD values that were within the predicted values. Moreover, most of the compounds were predicted to be nontoxic with the exception of compounds **1c** and **3c** both containing a picolyl substituent. Interestingly, all derivatives of **2** and **3** possessed poor clearance values while some of the derivatives of **1** including **1a-d**, **1f**, **1g**, and **1i** possessed moderate clearance values. Furthermore, all compounds displayed poor half-life values and poor to fair protein plasma binding (PPB) values. For example, the compounds with the best half-life values ($T_{1/2} > 0.7$) were **1a-f**, **1i**, **1k**, **2a**, **2b**, **2e**, and **3c** while compounds **1b-c** and **3b-c** were the only compounds to possess favourable protein plasma binding properties. A number of hydrogen acceptors (nHA) and number of hydrogen donors (nHD) of all compounds were within the predicted values.

Table 1. Summarised antitubercular activity against *Mtb* H₃₇R_v strain and cytotoxicity results of the benzylamine derivatives.

R =	X =	MIC ₉₀	IC ₅₀	R =	X =	MIC ₉₀	IC ₅₀
	H (1a)	22.66	>50		H (1h)	21.00	>50
	Br (2a)	22.26	>50		Br (2g)	20.39	>50
	I (3a)	25.45	>50		I (3h)	22.50	8.8
	H (1b)	20.78	>50		H (1i)	25.79	>50
	Br (2b)	20.59	>50		Br (2h)	22.66	>50
	I (3b)	29.62	>50		I (3i)	21.89	44.9
	H (1c)	20.44	>50		H (1j)	25.79	>50
	I (3c)	22.22	12.5		I (3j)	21.54	48.0
	H (1d)	20.35	>50		H (1k)	21.21	>50
	Br (2c)	20.04	>50				
	I (3d)	20.68	47.3				

(Table 1) contd....

	H (1e)	22.95	>50		H (1l)	21.94	>50
	Br (2d)	22.94	>50		Br (2i)	22.66	>50
	I (3e)	20.29	>50		I (3k)	21.84	>50
	H (1f)	25.79	>50		H (1m)	20.64	>50
	Br (2e)	20.04	>50		Br (2j)	22.05	>50
	I (3f)	25.02	>50				
	H (1g)	27.73	>50		H (1n)	20.67	>50
	Br (2f)	>125	>50		Br (2k)	25.74	>50
	I (3g)	22.62	>50		I (3l)	20.59	>50
Rifampicin	-	0.01	-	Emetine	-	-	0.01

Table 2. ADMET predictions of the benzylamine derivatives.

ID	MW	LogS	LogP	LogD	H-HT	CL	T _{1/2}	PPB (%)	nHA	nHD	Rules satisfied		
											GSK	Pfizer	Lipinski
1a	243.13	-2.51	3.02	3.01	-1	7.56	0.861	98.22	3	2	Yes	No	Yes
2a	321.040	-3.27	3.79	3.44	-1	2.04	0.757	98.44	3	2	Yes	No	Yes
3a	369.020	-4.10	4.06	3.30	-1	2.85	0.540	99.93	3	2	Yes	No	Yes
1b	257.140	-1.82	2.57	2.71	-1	9.78	0.862	87.18	3	2	Yes	Yes	Yes
2b	335.050	-2.61	3.47	3.31	-1	2.12	0.754	93.34	3	2	Yes	No	Yes
3b	383.040	-3.42	3.77	2.91	-1	4.11	0.542	88.20	3	2	Yes	No	Yes
1c	258.140	-0.08	1.40	1.43	+1	6.85	0.865	49.62	4	2	Yes	Yes	Yes
3c	384.030	-2.06	2.80	2.22	+1	2.93	0.755	56.48	4	2	Yes	No	Yes
1d	261.120	-3.16	3.25	3.25	-1	7.15	0.767	98.87	4	2	Yes	No	Yes
2c	339.030	-4.09	3.99	3.61	-1	2.11	0.577	99.05	4	2	Yes	No	Yes
3d	387.010	-4.57	4.24	3.56	-1	2.94	0.328	100.48	4	2	No	No	Yes
1e	369.020	-4.05	3.96	3.70	-1	4.06	0.712	99.57	3	2	Yes	No	Yes
2d	446.93	-4.76	4.56	3.71	-1	1.69	0.459	99.64	3	2	No	No	Yes
3e	494.920	-4.85	4.79	3.46	-1	2.24	0.252	100.56	3	2	No	No	Yes
1f	273.140	-3.41	3.06	3.18	-1	8.11	0.876	98.39	4	2	Yes	No	Yes
2e	351.050	-4.31	3.83	3.57	-1	2.33	0.794	98.63	4	2	Yes	No	Yes
3f	399.030	-4.71	4.10	3.58	-1	3.51	0.612	99.94	4	2	No	No	Yes
1g	261.120	-2.73	3.17	3.16	-1	8.60	0.595	98.93	4	2	Yes	No	Yes
2f	339.030	-3.59	3.91	3.46	-1	2.39	0.380	98.97	4	2	Yes	No	Yes
3g	387.010	-4.33	4.18	3.36	-1	3.21	0.196	100.54	4	2	No	No	Yes
1h	369.020	-4.06	4.09	3.41	-1	2.74	0.411	100.00	3	2	No	No	Yes
2g	446.93	-4.78	4.65	3.20	-1	1.63	0.214	100.05	3	2	No	No	Yes
3h	494.920	-4.93	4.90	2.95	-1	1.96	0.115	100.94	3	2	No	No	Yes
1i	273.140	-2.81	3.03	3.01	-1	8.84	0.802	98.74	4	2	Yes	No	Yes
2h	351.050	-3.75	3.86	3.43	-1	2.55	0.651	98.91	4	2	Yes	No	Yes
3i	399.030	4.13	4.13	3.41	-1	3.55	0.364	100.26	4	2	No	No	Yes
1j	335.050	-4.49	4.00	3.72	-1	2.82	0.697	98.98	3	2	No	No	Yes
3j	446.930	-5.44	4.65	3.35	-1	2.77	0.412	100.22	3	2	No	No	Yes
1k	379.040	-4.59	3.77	3.49	-1	3.70	0.860	99.45	5	2	Yes	No	Yes
1l	402.980	-4.56	4.51	3.97	-1	3.42	0.371	100.48	3	2	No	No	Yes
2i	480.890	-5.18	5.23	3.51	-1	1.82	0.218	100.55	3	2	No	No	Yes
3k	528.880	-5.06	5.47	3.30	-1	2.26	0.137	101.50	3	2	No	No	No
1m	387.010	-4.26	4.11	3.76	-1	4.67	0.346	100.46	4	2	No	No	Yes

(Table 2) contd....

2j	464.920	-4.94	4.74	3.71	-1	2.01	0.215	100.30	4	2	No	No	Yes
1n	311.050	-4.15	4.26	3.52	-1	4.84	0.511	100.02	3	2	No	No	Yes
2k	388.96	-5.02	4.93	3.18	-1	2.27	0.314	100.38	3	2	No	No	Yes
3l	436.940	-5.18	5.15	2.98	-1	2.62	0.196	101.19	3	2	No	No	Yes
Rif.	882.40	-2.35	3.32	1.89	+1	1.74	0.50	77.65	16	6	No	Yes	No

Abbreviations: MW-Molecular Weight: 100 – 600 g/mol, LogS (predicted aqueous solubility): -4 – 0.5 log mol/L, LogP (predicted octanol/water partition coefficient): 0 – 3, LogD (predicted lipophilicity at pH 7.4): 1 – 3, Human Hepatotoxicity (H H-T): -1 (nontoxic) – +1 (toxic), CL (Clearance): 5 – 15 mL/min/kg (<5 (low), 5 – 15 (moderate), >15 (high), Half-life ($T_{1/2}$): >3 hours (short half-life <3 hours), Protein Plasma Binding (PPB): < 90%, Number of Hydrogen Acceptors (nHA): 0 – 12, Number of Hydrogen Donors (nHD): 0 – 7, GSK's Rule: MW ≤ 400, LogP ≤ 4, Pfizer's Rule: LogP ≤ 3, Topological Polar Surface Area (TPSA) > 75, Lipinski's Rule: MW ≤ 500, LogP ≤ 5, Number of Hydrogen Acceptors (nHA) ≤ 10, Number of Hydrogen Donors (nHD) ≤ 5.

Further analysis of Table 2 results revealed that only two compounds (**1b**, **1c**) possessed the best predicted drug-like properties followed by **3b** and **3c**, which displayed poor predicted logP and clearance values respectively. In general, the use of phenyl substituents with or without halogen substituents (Br, Cl, F, I) led to poor drug-like predicted properties (e.g. **1a**, **1f**). Notably, the compounds with the best predicted drug-like properties possessed a methylene bridge without halogen substituents (**1b** and **1c**), thus, indicating its role in improving drug-like properties. All compounds satisfied Lipinski's rule with the exception of compound **3k** which also failed both Pfizer's and GSK's rules. In addition to **3k**, several compounds (e.g. **2d**, **3d**, **3e** and others) containing more than two halogen substituents (with the exception of **3f** and **3i**), failed both Pfizer's and GSK's rules. Finally, the predicted ADMET properties of Rifampicin, the approved antitubercular drug used as a reference showed a compound with favourable logP, logD and PPB values. However, Rifampicin was predicted to have high toxicity, poor clearance and half-life values, and it was also rejected by GSK's rule [39 - 41].

CONCLUSION

A total of 37 compounds were synthesised and successfully biologically evaluated against *Mycobacterium tuberculosis* (Mtb) H37RV strain. All compounds showed activity against Mtb at concentrations of > 20 μM < 28 μM with the exception of compound **2f** which was active against Mtb at higher concentrations (MIC₉₀ > 125 μM). The most active compounds, **2c** and **2e** possessed MIC₉₀ values of 20.04 μM each. Compounds with 5-bromo substituent were the most active against Mtb. Cytotoxicity results revealed compounds largely inactive against CHO cells with the exception of **3c**, **3d**, **3h**, **3i** and **3j** with **3i** being the most active with an MIC₅₀ value of 8.80 μM. Predicted ADMET properties of the synthesised compounds revealed that phenyl substituents and the presence of halogen substituents received unfavourable physicochemical properties while the introduction of methylene bridge received favourable physicochemical properties. This study has demonstrated the ability of benzylamine derivatives as possible future drug candidates for the treatment of tuberculosis.

LIST OF ABBREVIATIONS

TB	= Tuberculosis
WHO	= World Health Organization
MD-R TB	= Multidrug-resistance tuberculosis
XDR-TB	= Extensively drug-resistance tuberculosis
CHO	= Chinese Hamster ovarian

NIS	= N-iodosuccinimide
NBS	= N-bromosuccinimide
Mtb	= <i>Mycobacterium tuberculosis</i>
ADMET	= Adsorption, Distribution, Metabolism, Excretion and Toxicity
nHA	= Number of hydrogen acceptors
nHD	= Number of hydrogen donors

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

HUMAN AND ANIMAL RIGHTS

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

Not applicable.

FUNDING

The authors are thankful for financial support on this project from the University of Limpopo and the National Research Foundation (South Africa) through grant number TTK180412320177.

COMPETING INTEREST

The authors declare that they have no competing financial or personal interests.

ACKNOWLEDGEMENTS

The authors wish to thank the University of Limpopo, Ms. Lerato Raphoko (University of Limpopo) for mass spectrometric data and the Drug Discovery and Development Centre (H3D) at the University of Cape Town for Mtb and cytotoxicity assay data.

REFERENCES

- [1] *Global Tuberculosis Report*; World Health Organization, **2017**.
- [2] *Global Tuberculosis Report*; World Health Organization, **2018**.
- [3] *Global Tuberculosis Report*; World Health Organization, **2019**.
- [4] *Global Tuberculosis Report 2020*; World Health Organization, **2020**.
- [5] Raphoko, L.A.; Lekgau, K.; Lebepe, C.M.; Leboho, T.C.; Matsebatlela, T.M.; Nxumalo, W. Synthesis of novel quinoxaline-alkynyl derivatives and their anti-*Mycobacterium tuberculosis* activity. *Bioorg. Med. Chem. Lett.*, **2021**, 35127784 [http://dx.doi.org/10.1016/j.bmcl.2021.127784] [PMID: 33422606]

- [6] Dheda, K.; Tomasicchio, M.; Reuter, A.; Davids, M.; Calligaro, G.; Furin, J.; van Helden, P.; Warren, R.; Scriba, T. Tuberculosis. *Encyclopedia of Respiratory Medicine*; Elsevier, **2022**, pp. 75-98. [http://dx.doi.org/10.1016/B978-0-08-102723-3.00248-1]
- [7] Li, Y.; Liu, Y.; Wang, Y.; Tang, S.; Song, D. Synthesis and biological evaluation of new 13-n-nonylprotoberberine derivatives as antitubercular agents. *Acta Pharm. Sin. B*, **2013**, 3(1), 38-45. [http://dx.doi.org/10.1016/j.apsb.2012.12.004]
- [8] Bahraminia, F.; Zangiabadian, M.; Nasiri, M.J.; Fattahi, M.; Goudarzi, M.; Ranjbar, R.; Imani Fooladi, A.A. Rifampicin resistance in *Mycobacterium tuberculosis* in Iran: a two-centre study. *New Microbes New Infect.*, **2021**, 42100909 [http://dx.doi.org/10.1016/j.nmni.2021.100909] [PMID: 34336229]
- [9] Chisompola, N.K.; Streicher, E.M.; Dippenaar, A.; Whitfield, M.G.; Tembo, M.; Mwanza, S.; Warren, R.M.; Sampson, S.L. Drug resistant tuberculosis cases from the Copperbelt province and Northern regions of Zambia: Genetic diversity, demographic and clinical characteristics. *Tuberculosis (Edinb.)*, **2021**, 130, 102122. [http://dx.doi.org/10.1016/j.tube.2021.102122] [PMID: 34517268]
- [10] Santivañez-Veliz, M.; Pérez-Silanes, S.; Torres, E.; Moreno-Figuri, E. Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis. *Bioorg. Med. Chem. Lett.*, **2016**, 26(9), 2188-2193. [http://dx.doi.org/10.1016/j.bmcl.2016.03.066] [PMID: 27025343]
- [11] El-Azab, A.S.; Mary, Y.S.; Abdel-Aziz, A.A.M.; Miniyar, P.B.; Armaković, S.; Armaković, S.J. Synthesis, spectroscopic analyses (FT-IR and NMR), vibrational study, chemical reactivity and molecular docking study and anti-tubercular activity of condensed oxadiazole and pyrazine derivatives. *J. Mol. Struct.*, **2018**, 1156, 657-674. [http://dx.doi.org/10.1016/j.molstruc.2017.12.018]
- [12] Pontali, E.; Sotgiu, G.; D'Ambrosio, L.; Centis, R.; Migliori, G. B. Bedaquiline and multidrug-resistant tuberculosis: A systematic and critical analysis of the evidence. *Eur Respir J Title*, **2016**, 394-402. [http://dx.doi.org/10.1183/13993003.01891-2015]
- [13] Singh, B.; Cocker, D.; Ryan, H.; Sloan, D. J. Linezolid for drug-resistant pulmonary tuberculosis. *Cochrane Database of Systematic Reviews*; John Wiley and Sons Ltd, **2019**. [http://dx.doi.org/10.1002/14651858.CD012836.pub2]
- [14] Mohr, E.; Hughes, J.; Reuter, A.; Trivino Duran, L.; Ferlazzo, G.; Daniels, J.; De Azevedo, V.; Kock, Y.; Steele, S.J.; Shroufi, A.; Ade, S.; Alikhanova, N.; Benedetti, G.; Edwards, J.; Cox, H.; Furin, J.; Isaakidis, P. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. *Eur. Respir. J.*, **2018**, 51(6), 1800017.. [http://dx.doi.org/10.1183/13993003.00017-2018] [PMID: 29724920]
- [15] https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs
- [16] Tornheim, J. A.; Dooley, K. E. Challenges of TB and HIV Co-Treatment: Updates and Insights. *Current opinion in HIV and AIDS. element*, **2018**, 486-491. [http://dx.doi.org/10.1097/COH.0000000000000495]
- [17] Shehzad, A.; Rehman, G.; Ul-Islam, M.; Khattak, W. A.; Lee, Y. S. Challenges in the development of drugs for the treatment of tuberculosis. *The BJID*, **2013**, 74-81. [http://dx.doi.org/10.1016/j.bjid.2012.10.009]
- [18] Chiang, C.Y.; Van Weezenbeek, C.; Mori, T.; Enarson, D.A. Challenges to the global control of tuberculosis. *Respirology*, **2013**, 18(4), 596-604. [http://dx.doi.org/10.1111/resp.12067] [PMID: 23551328]
- [19] Living with the challenges of treating tuberculosis. *Breathe (Sheff.)*, **2015**, 11(1), 71-72. [http://dx.doi.org/10.1183/20734735.000115] [PMID: 26306106]
- [20] Aibana, O.; Dauria, E.; Kiriazova, T.; Makarenko, O.; Bachmaha, M.; Rybak, N.; Flanigan, T. P.; Petrenko, V.; Becker, A. E.; Murray, M. B. Patients' perspectives of tuberculosis treatment challenges and barriers to treatment adherence in Ukraine: A qualitative study. *BMJ Open*, **2020**, 10(1), e032027. [http://dx.doi.org/10.1136/bmjopen-2019-032027]
- [21] Rowland, K. Totally drug-resistant TB emerges in India. *Nature*, **2012**. [http://dx.doi.org/10.1038/nature.2012.9797]
- [22] Dorman, S.E.; Nahid, P.; Kurbatova, E.V.; Goldberg, S.V.; Bozeman, L.; Burman, W.J.; Chang, K.C.; Chen, M.; Cotton, M.; Dooley, K.E.; Engle, M.; Feng, P.J.; Fletcher, C.V.; Ha, P.; Heilig, C.M.; Johnson, J.L.; Lessem, E.; Metchock, B.; Miro, J.M.; Nhung, N.V.; Pettit, A.C.; Phillips, P.P.J.; Podany, A.T.; Purfield, A.E.; Robergeau, K.; Samaneka, W.; Scott, N.A.; Sizemore, E.; Vernon, A.; Weiner, M.; Swindells, S.; Chaisson, R.E. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. *Contemp. Clin. Trials*, **2020**, 90, 105938.. [http://dx.doi.org/10.1016/j.cct.2020.105938] [PMID: 31981713]
- [23] Jayoung Chae, Y. C. M. T.; J., C. Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis. *J Biosci Bioeng*, **2021**, 132(6), 543-551. [http://dx.doi.org/10.1016/j.jbiosc.2021.08.009]
- [24] D'Souza, S.; D. P. S. E. S. B. R. M. R. rabin, A.S.S.D.A.; D'Souza, S Physicochemical and biological evaluation of curdlan-poly (lactico-glycolic acid) nanoparticles as a host-directed therapy against *mycobacterium tuberculosis*. *J Pharm Sci.*, **2022**, 111(2), 469-478. [http://dx.doi.org/10.1016/j.xphs.2021.09.012]
- [25] Meindl, W.R.; Von Angerer, E.; Schoenenberger, H.; Ruckdeschel, G. Benzylamines: synthesis and evaluation of antimycobacterial properties. *J. Med. Chem.*, **1984**, 27(9), 1111-1118. [http://dx.doi.org/10.1021/jm00375a005] [PMID: 6433022]
- [26] White, G.V.; Edgar, E.V.; Holmes, D.S.; Lewell, X.Q.; Liddle, J.; Polyakova, O.; Smith, K.J.; Thorpe, J.H.; Walker, A.L.; Wang, Y.; Young, R.J.; Hovnanian, A. Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome. *Bioorg. Med. Chem. Lett.*, **2019**, 29(6), 821-825. [http://dx.doi.org/10.1016/j.bmcl.2019.01.020] [PMID: 30691925]
- [27] Cai, S.; Zhu, G.; Cen, X.; Bi, J.; Zhang, J.; Tang, X.; Chen, K.; Cheng, K. Synthesis, structure-activity relationships and preliminary mechanism study of N-benzylideneaniline derivatives as potential TLR2 inhibitors. *Bioorg. Med. Chem.*, **2018**, 26(8), 2041-2050. [http://dx.doi.org/10.1016/j.bmc.2018.03.001] [PMID: 29534935]
- [28] Belz, T.; Ihmaid, S.; Al-Rawi, J.; Petrovski, S. Synthesis characterization and antibacterial, antifungal activity of n-(benzyl carbamoyl or carbamothioyl)-2-hydroxy substituted benzamide and 2-benzyl amino-substituted benzoxazines. *Int. J. Med. Chem.*, **2013**, 2013, 1-20. [http://dx.doi.org/10.1155/2013/436397] [PMID: 25374690]
- [29] Mojena, M.; Povo-Retana, A.; González-Ramos, S.; Fernández-García, V.; Regadera, J.; Zazpe, A.; Artaiz, I.; Martín-Sanz, P.; Ledo, F.; Boscá, L. Benzylamine and thenylamine derived drugs induce apoptosis and reduce proliferation, migration and metastasis formation in melanoma cells. *Front. Oncol.*, **2018**, 8(AUG), 328. [http://dx.doi.org/10.3389/fonc.2018.00328] [PMID: 30191142]
- [30] Ameta, R.K.; Singh, M.; Kale, R.K. Synthesis and structure-activity relationship of benzylamine supported platinum(IV) complexes. *New J. Chem.*, **2013**, 37(5), 1501-1508. [http://dx.doi.org/10.1039/c3nj41141a]
- [31] Marti, L.; Abella, A.; Carpé, C.; Palacín, M.; Testar, X.; Zorzano, A. Combined treatment with benzylamine and low dosages of vanadate enhances glucose tolerance and reduces hyperglycemia in streptozotocin-induced diabetic rats. *Diabetes*, **2001**, 50(9), 2061-2068. [http://dx.doi.org/10.2337/diabetes.50.9.2061]
- [32] Heravi, M. M.; Zadsirjan, V. Prescribed drugs containing nitrogen heterocycles: An overview. *RSC Adv.*, **2020**, 10(72), 4247-44311. [http://dx.doi.org/10.1039/D0RA09198G]
- [33] Zysman-Colman, E.; Arias, K.; Siegel, J.S. Synthesis of Arylbromides from Arenes and N-bromosuccinimide Bromosuccinimide (NBS) in Acetonitrile - A Convenient Method for Aromatic Bromination. *Can. J. Chem.*, **2009**, 87(2), 440-447. [http://dx.doi.org/10.1139/V08-176]
- [34] Afanasyev, O. I.; Kuchuk, E.; Usanov, D. L.; Chusov, D. Reductive amination in the synthesis of pharmaceuticals. *Chemical Reviews*, **2019**, 11, 11857-11911. [http://dx.doi.org/10.1021/acs.chemrev.9b00383]
- [35] Soares de Melo, C.; Feng, T.S.; van der Westhuyzen, R.; Gessner, R.K.; Street, L.J.; Morgans, G.L.; Warner, D.F.; Moosa, A.; Naran, K.; Lawrence, N.; Boshoff, H.I.M.; Barry, C.E., III; Harris, C.J.; Gordon, R.; Chibale, K. Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of *Mycobacterium tuberculosis*: Structure activity relationships and ADME characterization. *Bioorg. Med. Chem.*, **2015**, 23(22), 7240-7250. [http://dx.doi.org/10.1016/j.bmc.2015.10.021] [PMID: 26522089]
- [36] Mosmann, T. *Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays*; , **1983**.
- [37] Xiong, G.; Wu, Z.; Yi, J.; Fu, L.; Yang, Z.; Hsieh, C.; Yin, M.; Zeng, X.; Wu, C.; Lu, A.; Chen, X.; Hou, T.; Cao, D. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions

- of ADMET properties. *Nucleic Acids Res.*, **2021**, 49(W1), W5-W14. [http://dx.doi.org/10.1093/nar/gkab255] [PMID: 33893803]
- [38] ADMETlab2.0. Available at: <https://admetmesh.scbdd.com/service/evaluation/cal>
- [39] Wang, J.-L.; Li, H.-J.; Wu, Y.-C. Divergent synthesis of marine natural products siphonodictyal b, corallidictyals c/d, and liphagal based on the early presence of an aldehyde group instead of a late-stage introduction. *J Org Chem*, **2018**, 83(15), 8716-8723. [http://dx.doi.org/10.1021/acs.joc.8b00989]
- [40] Espacenet-search results, Available at: <https://worldwide.espacenet.com/patent/search/family/033131870/publication/WO2004087687A1?q=WO2004087687A1>
- [41] Baxter, E. W.; Johnson, W Reductive aminations of carbonyl compounds with borohydride and borane reducing agents. [http://dx.doi.org/10.1002/0471264180.or059.01]

© 2023 Sedibana and Leboho

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: <https://creativecommons.org/licenses/by/4.0/legalcode>. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.